
Pfizer’s New Forecast: Reasons to Buy or Beware?
A Closer Look at Pfizer’s Projections Despite facing unusual pressure from shareholders eager for a shake-up, Pfizer (PFE 2.29%) remains optimistic about its future. The pharmaceutical giant recently unveiled its forecasts for 2024 and 2025, emphasizing a commitment to cost control and